{
    "article_id": "c6cf4ec8-dbd8-4538-a084-fbfbd0671286",
    "extracted_text": "IJC\nInternational Journal of Cancer\nfi\nA bronchial-airway gene-expression classi er to improve\nthe diagnosis of lung cancer: Clinical outcomes and\ncost-effectiveness analysis\nElviraD\u2019Andrea 1,NiteeshKumarChoudhry1,BenjaminRaby2,GeraldLawrenceWeinhouse3andMehdiNajafzadeh1\n1DivisionofPharmacoepidemiologyandPharmacoeconomics,DepartmentofMedicine,BrighamandWomen\u2019sHospitalandHarvardMedicalSchool,\nBoston,MA,USA\n2ChanningDivisionofNetworkMedicine,DepartmentofMedicine,BrighamandWomen\u2019sHospital,HarvardMedicalSchool,Boston,MA,USA\n3DivisionofPulmonaryandCriticalCareMedicine,BrighamandWomen\u2019sHospital,Boston,MA,USA\nBronchoscopyisthesafestprocedureforlungcancerdiagnosiswhenaninvasiveevaluationisrequiredafterimaging\nprocedures.However,itssensitivityisrelativelylow,especiallyforsmallandperipherallesions.Weassessedbenefitsand ygoloimedipE\ncostsofintroducingabronchialgene-expressionclassifier(BGC)toimprovetheperformanceofbronchoscopyandtheoverall\ndiagnosticprocessforearlydetectionoflungcancer.Weuseddiscrete-eventsimulationtocompareclinicalandeconomic\noutcomesoftwodifferentstrategieswiththestandardpracticeinformerandcurrentsmokerswithindeterminatenodules:\n(i)location-basedstrategy\u2014integratedtheBGCtothebronchoscopyindication;(ii)simplifiedstrategy\u2014extendeduseof\nbronchoscopyplusBGCalsoonsmallandperipherallesions.Outcomesmodeledwererateofinvasiveprocedures,quality-\nrecnaC\nadjusted-life-years(QALYs),costsandincrementalcost-effectivenessratios.Comparedtothestandardpractice,thelocation-\nbasedstrategy(i)reducedabsoluterateofinvasiveproceduresby3.3%withoutincreasingcostsatthecurrentBGCmarket\nprice.ItresultedinsavingswhentheBGCpricewaslessthan$3,000.Thesimplifiedstrategy(ii)reducedabsoluterateof\ninvasiveproceduresby10%andimprovedquality-adjustedlifeexpectancy,producinganincrementalcost-effectivenessratio\nof$10,109perQALY.Inpatientswithindeterminatenodules,bothBGCstrategiesreducedunnecessaryinvasiveproceduresat\nhighriskofadverseevents.Moreover,comparedtothestandardpractice,thesimplifieduseofBGCforcentralandperipheral\nlesionsresultedinlargerQALYsgainsatacceptablecost.Thelocation-basediscost-savingifthepriceofclassifierdeclines.\nIntroduction Indeterminate pulmonary nodules, defined as noncalcified\nDespite declining smoking rates, lung cancer remains the solidlesions with a risk ofmalignancybetween 5 and 60%,are\nleading cause of cancer-related death and was responsible for frequentlyidentifiedonLDCTimaging.4Insuchcases,acareful\n155,870 deaths in the US in 2017.1Over the decades, surgical, assessment,basedonsurgicalrisk,abilitytobiopsyandindivid-\nradiotherapeutic and chemotherapeutic advances have not ualpreferences,isessentialtodecidebetweensurveillanceimag-\nimproved5-yearsurvival,mainlybecausethemajorityofcases ing and invasive evaluation.5 When an invasive evaluation is\narestilldiagnosed atalatestage,forwhichthesurvivalrateis required, the procedure adopted is selected based on consider-\nverylow.1Thus,therehasbeenincreasingenthusiasmforear- ations such as location and lesion size, adenopathy, safety and\nlier detection with low-dose computed tomography (LDCT), patients\u2019 characteristics.6,7 Bronchoscopy is the procedure with\nreducing lung cancer mortality by up to 20% among current thesmallestrateofcomplicationsbutalsorelativelylowsensitiv-\nandformersmokers.2,3 ity, especially for small and peripheral lesions.6,7 In contrast,\nKeywords:lungcancer,earlydetectionofcancer,genomics,bronchoscopy,cost\u2013benefitanalysis\nAbbreviations:18F-FDGPET:18F-fluorocholinepositronemissiontomography;AEGIS:AirwayEpithelialGeneExpressionintheDiagnosis\nofLungCancerStudies1and2;BGC:bronchial-airwaygene-expressionclassifier;ICER:incrementalcost-effectivenessratio;LDCT:low-dose\ncomputedtomography;POM:probabilityofmalignancy;QALY:quality-adjustedlifeyears;TTNA/B:transthoracicneedleaspirationorbiopsy\nAdditionalSupportingInformationmaybefoundintheonlineversionofthisarticle.\nConflictofinterest:Nopotentialconflictsofinterestweredisclosed.\nDOI:10.1002/ijc.32333\nHistory:Received28Dec2018;Accepted3Apr2019;Online11Apr2019.\nCorrespondenceto:ElviraD\u2019Andrea,MD,MPH,DivisionofPharmacoepidemiologyandPharmacoeconomics,DepartmentofMedicine\nBrighamandWomen\u2019sHospitalandHarvardMedicalSchool,1620TremontStreet,Suite3030,Boston,MA02120,USA,\nE-mail:edandrea@bwh.harvard.edu\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC10970215,\n782 Cost-effectivenessofabronchialgenomicdevice 2020,\n3,\nDownloaded\nWhat\u2019snew?\nfrom\nBronchoscopyisthesafestprocedureforlungcancerdiagnosiswhenaninvasiveevaluationisrequiredfollowingimaging\nprocedures.Itssensitivityisrelativelylow,however.Thisstudyassessesbenefitsandcostsofintroducingabronchialgene- https://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nexpressionclassifier(BGC)toimprovetheperformanceofbronchoscopyandtheoverallprocessforearlydetectionoflung\ncancer.Whencomparedwithstandardpractice,anextendeduseofBGCfordiagnosisofcentralandperipheralpulmonary\nlesionsimprovesquality-adjustedlifeexpectancy,reducesunnecessaryinvasiveprocedures,andhasanincrementalcost-\neffectivenessratioofUS$10,109perquality-adjustedlifeyeargained,withoutincreasingmortality.\ntransthoracicneedlebiopsyandwedgeresectionhaveasatisfying (i.e., US, Canada, Irland)\u2014the AEGIS-1 and AEGIS-2 trials\ndiagnosticperformancebutareassociatedwithsubstantialcom- (Table 1).9 We assumed that the patients in our model were\nplications.6,7 Moreover, because nondiagnostic bronchoscopic allpotentiallyoperativecandidates.\nexaminations are common, patients often require further inva- Figure1illustratesourmodelforthethreediagnosticstrat-\nWiley\nsive investigations after bronchoscopy, increasing their overall egies: (a) standard diagnostic strategy, following the current\nguidelines6,7;(b)location-baseddiagnosticstrategy,integrating Online\nriskofcomplicatedproceduresandcosts.\nIn early 2015, 8 million Americans became eligible for the bronchial-airway gene-expression classifier (BGC) to the Library\nbronchoscopyindicationonthecurrentguidelines;(c)simplified\nannual LDCT screeningthroughMedicareprogramorprivate\ninsurance.8 This is expected to increase the number of inde- diagnostic strategy, with an extended use of bronchoscopy plus on [10/08/2023].\nterminate pulmonary nodules detected and, consequently, BGCalsoforperipherallesions.\nnondiagnostic bronchoscopic examinations and complicated Each patient was tracked throughout a time horizon of\nprocedures inpatients ultimately found with benign lesions.2,9 2years after the initial lung cancer screening, which is the See\nsurveillanceperiodrecommendedbyguidelines.6Weassumed the\nMethods that improve the diagnostic performance of bron-\nTerms\nchoscopy have the potential to improve clinical outcomes, that all patients entered the model already with a suspected\navoid complications and potentially lower healthcare costs. lesion identified on LDCT. For each individual, a specific age, and\nConditions\nRecently, the Airway Epithelial Gene Expression in the Diag- clinical probability of malignancy (POM) and a cancerous or\nnosisofLungCancer(AEGIS)studiesshowedthatcombining no cancerous lesion status were assigned based on the\nbronchoscopy with a bronchial gene-expression classifier can observed distribution of those variable in the AEGIS trials. (https://onlinelibrary.wiley.com/terms-and-conditions)\nsignificantly improve diagnostic sensitivity in current and for- We assumed all affected patients had cancers at Stage I at the\nmer smokers, independent of lesion size, location, stage and entry, and lung cancer progression to be a function of time.\npresence of adenopathy.9 The classifier uses both information Thus, malignancies, that were undetected at the end of the\nfirstyear,progressedatStageIIwithinthesubsequentyear.\non cancerous gene-expression patterns in bronchial epithe-\nlium cells, collected by brushing the proximal airways during\nthe bronchoscopy, and demographic factors such as age, gen-\nDiagnosticstrategies\nder and pack-years smoking. The clinical utility of the classi-\nPatients who were at intermediate or unknown POM were\nfier,asadjunctexam tothebronchoscopy,istobetteridentify\nscreened with 18F-fluorocholine positron emission tomography\ncandidates who do not require further invasive investigations\n(18F-FDGPET)imaging,whilethosewithhighPOMunderwent\namongthosewithindeterminatenodules.9,10\ndirectlysurgery.PatientswithalowPOMormild/low18F-FDG on\nWeestimatedclinicalbenefitsandcostsofusingtheclassi- Wiley\nnoduleuptakereceivedtworepeatLDCTwithinthesubsequent\nfier for the diagnosis of lung cancer in patients with indeter- 2years,accordingtothewatchfulwaitingapproach.6Ifacancer Online\nminate pulmonary nodules who are currently eligible for\nprogression was detected during the 2-year follow-up, these Library\nLDCTlungcancerscreening.\npatientsweresurgicallytreated.\nfor\nPatients with moderate/intense 18F-FDG nodule uptake rules\nMethods faced different diagnostic and treatment pathways according\nof\nDecisionmodel tothethreealternativestrategiesofourmodel. use;\nOA\nWe developed a discrete-event simulation model using Arena, In the standard strategy, patients were referred to bron-\narticles\nversion15.00(RockwellAutomation,Milwaukee,WI),tosim- choscopy,transthoracicneedleaspirationorbiopsy(TTNA/B)\nulate the diagnostic pathways and progression of pulmonary or surgery, consistent with the current recommendations.6,7 are\ngoverned\nlesions among current or former smokers undergoing LDCT We assumed that all patients with central or central and\nscreeningforsuspectedlungcancer.Wegeneratedahypothet- peripheral lesions were first investigated with bronchoscopy\nby\nical cohort of 10,000 patients with the baseline characteristics and those with only peripheral lesions with TTNA/B or sur- the\nsimilartothecohortsfromtwomulticenterprospectiveobser- gery.6,7 Because of the highrate offalse negatives at the bron- applicable\nvational studies that enrolled patients undergoing bronchos- choscopy, a nondiagnostic bronchoscopic result (true and\ncopy from different practice settings and geographic locations false negatives) led to further invasive investigations; while a Creative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\nD\u2019Andreaetal. 783 2020,\n3,\nDownloaded\nTable1.Modelparametersandassumptions\nfrom\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nMen 440(69) Silvestrietal.9\nSmokingstatus Silvestrietal.9\nCurrent 315(49)\nFormer 324(51)\nTobaccouse\u2014packyear 43(24\u201363) Silvestrietal.9\nLesionlocation Silvestrietal.9\nCentral 225(35)\nPeripheral 194(30)\nWiley\nCentralandperipheral 192(30)\nUnknown 28(5) Oynlgineo\nDistributionofclinicalprobabilityofmalignancy(POM) Silvestrietal.9 Lliborairym\nLow 62(10)\non\nIntermediate 101(16) e[1d0/0i8p/20E23].r\nHigh 426(67)\nUnknown 50(7)\nProbabilityofmalignancywithinPOMcategories Silvestrietal.9 Seeec\nthne\nLow 3(5) TaeCrms\nIntermediate 41(41)\nand\nHigh 405(95)\nConditions\n(https://onlinelibrary.wiley.com/terms-and-conditions)\nSensitivitystratifiedbyPOM\nLow 0.33 \u03b2(1,2)\nIntermediate 0.41 \u03b2(17,24)\nHigh 0.79 \u03b2(320,85)\nUndefined 0.82 \u03b2(31,7)\nSpecificity 1.0 \u2013\nBronchoscopy+classifier Silvestrietal.9\nSensitivitystratifiedperPOM\nLow 1.0 \u03b2(2,0.1) on\nIntermediate 0.88 \u03b2(21,3) Wiley\nHigh 0.89 \u03b2(77,10) Online\nUndefined 1.0 \u03b2(7,0.1)\nLibrary\nSpecificitystratifiedperPOM Silvestrietal.9\nLow 0.56 \u03b2(33,26) for\nrules\nIntermediate 0.48 \u03b2(29,31)\nof\nHigh 0.29 \u03b2(6,15) use;\nUndefined 0.33 \u03b2(29,31) OA\narticles\n18F-FDGPET Gouldetal.14\nSensitivity 0.942 \u03b2(212,13) are\ngoverned\nSpecificity 0.831 \u03b2(187,38)\nTTNA(orTTNB) Riveraetal.7\nby\nSensitivity 0.90 \u03b2(90,10) the\nSpecificity 0.97 \u03b2(97,3) applicable\n(Continues)\nCreative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\n784 Cost-effectivenessofabronchialgenomicdevice 2020,\n3,\nDownloaded\nTable1.Modelparametersandassumptions(Continued)\nfrom\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nLobectomy/segmentectomy 0.43 \u03b2(43,57)\nWedgeresection 0.57 \u03b2(57,43)\nInvasiveproceduresafterBC+BGC Fergusonetal.13\npositiveresults\nTTNA(orTTNB) 0.69 \u03b2(69,31)\nSurgicalprocedures 0.31 \u03b2(31,69)\nProbabilityofpneumothorax(afterBC) 0.03 N(0.03,0.005) Gouldetal.6\nProbabilityofpneumothorax(afterTTNA/B) 0.15 \u03b2(15,85) Gouldetal.6\nProbabilityofdeath(afterlobectomy/ 0.015 \u03b2(1.5,98.5) Riveraetal.,7Yangetal.16\nsegmentectomy)\nWiley\nProbabilityofdeath(afterwedgeresection) 0.005 \u03b2(0.5,99.5) Gouldetal.6\nProbabilityofdeathforStageIcancer(peryear) 0.05 \u03b2(5,95) IELCAPI17 Online\nProbabilityofdeathforStageIIcancer(peryear) 0.25 \u03b2(25,75) Wisniveskyetal18 Library\nUtilities\non\nStageIcancer 0.58 \u03b2(0.64,0.47) Trippolietal.19 [10/08/2023].\nStageIIcancer 0.53 \u03b2(0.61,0.54) Trippolietal.19\nSurgicalprocedures 0.56 \u03b2(0.63,0.50) Trippolietal.19\nPneumothorax 0.58 \u03b2(0.64,0.57) Nafeesetal.20 See\nthe\nBaseline 1.003\u20130.0031Age Sullivanetal.21 Terms\nCosts\nand\nWedgeresection 18,854 n(18,854,1885.4) SupportingInformationAppendixS1\nConditions\nLobectomy/segmentectomy 22,660 n(22,660,2,266) SupportingInformationAppendixS1\nTTNA(orTTNB) 2,483 n(2,483,248.3) SupportingInformationAppendixS1\n(https://onlinelibrary.wiley.com/terms-and-conditions)\nBronchoscopy 3,249 n(3,249,324.9) SupportingInformationAppendixS1\nBGC 2,865 n(2,865,286.5) SupportingInformationAppendixS1\nLDCTscan2 438 n(438,43.8) SupportingInformationAppendixS1\nF-FDGPET 1,438 n(1,438,143.8) SupportingInformationAppendixS1\n1CohortcharacteristicsrefertothoseoftheAEGIS-1andAEGIS-2studies.9\n2Follow-upconsistsofthreeLDCTscanswithinatimeframeof2years.6,7\nAbbreviations:BGC,bronchial-airwaygene-expressionclassifier;BC,bronchoscopy;18F-FDGPET,18F-fluorocholinepositronemissiontomography;LDCT,\nlow-dosecomputedtomography;POM,probabilityofmalignancy;TTNA,transthoracicneedleaspiration;TTNB,transthoracicneedlebiopsy.\nnegative result at TTNA/B or surgery directed patients to that all patients with a nondiagnostic result (true and false\non\nsurveillance.AdiagnosisofcanceratbronchoscopyorTTNA/B negatives) at bronchoscopy and negative result at BGC were\nWiley\nled to a curative surgery (Fig. 1a). Throughout the article, we referred to follow-up. All the other care decisions were\nOnline\nreferredtowedgeresectionorextentofresection(lobectomyand unchangedfromthestandardstrategy(Fig.1b).\nsegmentectomy), for both diagnoses of suspected nodules and The simplified strategy uses a bronchoscopy plus BGC as Library\ndefinitive management of malignancies, like surgery. Among diagnostic tool for all patients with moderate/intense 18F-FDG\nfor\npatients directed to surgery, we assumed that 57% underwent noduleuptake,regardlessofwherethelesionislocated,because rules\nwedgeresectionandtherestextentofresection(93%lobectomy ofthehighnegativepredictivevalueoftheBGCanalysisforthe\nof\nand7%segmentectomy10\u201313;Table1). peripheralcancers.9Thesubsequentcaremanagementremained use;\nOA\nIn the location-based strategy, bronchoscopy plus BGC unchangedfromthestandardstrategy(Fig.1c).\narticles\nwere used for patients with moderate/intense 18F-FDG nodule By creating identical clones of our cohort and assigning\nuptake and central or central and peripheral lesions, and them to different strategies, we compared diagnostic-related are\ngoverned\nTTNA/B or surgery for those with only peripheral nodules. differences in outcomes. Because the recommended approach\nAs before, a diagnosis of cancer was assumed to lead to a for the clinical management of undefined nodules in patients\nby\ncurativesurgery.Weassumedthatphysiciansreferredpatients at low POM is the watchful waiting approach, and the rec- the\nat intermediate risk of cancer to more invasive procedures for ommendedapproachinpatientsathighPOMismostlyasur- applicable\ndiagnostic confirmation, and their referrals did not change gical approach, the use of the BGC in those two groups is\nbased on a positive BGC result. On the contrary, we assumed limited. Thus, our base-case analysis focused on patients at Creative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\nD\u2019Andreaetal. 785 2020,\n3,\nDownloaded\n(a)\nfrom\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nWiley\nOynlgineo\nLliborairym\non\ne[1d0/0i8p/20E23].r\n(b)\nSeeec\nthne\nTaeCrms\nand\nConditions\n(https://onlinelibrary.wiley.com/terms-and-conditions)\n(c)\non\nWiley\nOnline\nLibrary\nfor\nrules\nof\nuse;\nOA\narticles\nare\ngoverned\nby\nthe\napplicable\nFigure1.Legendonnextpage.\nCreative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\n786 Cost-effectivenessofabronchialgenomicdevice 2020,\n3,\nDownloaded\nintermediate POM, who can achieve a greater benefit from Theresultsarereportedasincrementalnetmonetarybenefitat\nthe use of the BGC. We excluded from the base-case analysis awillingness-to-paythresholdof$100,000perQALY.\nfrom\nthe patients at unknown risk because of high prevalence of We performed probabilistic sensitivity analyses by chang-\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\ncancers and similarity to high POM group. Additional analyses ing all model parameters simultaneously.25 We sampled\nonthesesubgroupsarepresentedintheSupportingInformation. 10,000independentsetsofinputparametersfromtheirproba-\nbility distributions and, for each set, we modeled a cohort of\nDatasources 10,000 hypothetical patients per strategy.26,27 The results are\nWe modeled sensitivity, specificity, positive and negative pre- reportedusingacost-effectivenessplane(SupportingInforma-\ndictive values of bronchoscopy and bronchoscopy plus BGC tion)andincrementalcost-effectivenessacceptabilitycurves.\nbased on the AEGIS studies.9 Other data were derived from\npeer-reviewedliterature6,7,14\u201318(Table1).\nResults\nThe median age (63, interquartile range [IQR] 55\u201371years),\nModeloutcomes\nsmoking status (current or former smokers who quit within\nWe estimated the number of procedures with high risk of Wiley\nthe past 15years) and median pack-year history of cigarette\nadverse events (i.e., surgery and TTNA/B), cancer cases who smoking (43, IQR 24\u201363 pack-year) of our cohort were con- Online\nwent undetected and progressed to Stage II, and surgery-\nsistent with the eligibility criteria for the annual LDCT lung Library\nrelated and cancer-related deaths across the three strategies.\ncancer screening covered by Medicare program and other\nCosts, quality-adjustedexpectedlifeyears (QALYs) andincre- on\ncommercialinsuranceintheUS28,29(Table1).\n[10/08/2023].\nmental cost-effectiveness ratios (ICERs) were estimated; the\nresults were also presented in a cost-effectiveness plane to\nfacilitate comparisons. Because of the 2-year time horizon, Base-caseanalysis\nSee\ncosts and QALYs were not discounted. The analysis was con- Thebase-caseanalyses,comparingtheresultsofthreealternative the\nductedfromahealthcareperspective. strategies for patients with solid nodules at intermediate POM Terms\nare presentedinTable 2.Cost-effectiveness frontiers are shown and\nQuality-of-lifeweights in Figure 2. Additional results, including patients from other Conditions\nHealth-relatedquality-of-lifeweightsassociatedwitheachhealth POMcategories,arepresentedintheSupportingInformation.\nstateinthemodelwerederivedfromthepeer-reviewedliterature The standard diagnostic strategy produced average quality- (https://onlinelibrary.wiley.com/terms-and-conditions)\n(Table 1),19,20 and age-specific baseline quality-of-life estimates adjusted life expectancy of 12.13 QALYs and average 2-year\nfromtheMedicalExpenditurePanelSurvey.21Wepenalizedthe costs of$11,111 per patient.Adoptingthe location-based strat-\nQALYs lost due to mortality events based on patients\u2019 age- egy produced similar quality-adjusted life expectancy (12.129\nspecificlifeexpectancyperpublishedUSlifetables.\nQALYs)andaverage2-year costs($11,093)perpatient,assum-\ning the BGC cost of $2,865. The simplified strategy improved\nCosts quality-adjusted life expectancy to 12.20 QALYs and increased\nOnlydirectmedicalcostswereincluded.Weusedthe2017national average 2-year costs to $11,818. As a result, the location-based\nMedicarefeescheduletoderivecostofmostservicesbecauseitis strategy was almost equivalent to the standard diagnostic\nwidelyusedbycommercialpayersasareferenceorbenchmark.22,23 strategy while the simplified strategy achieved higher quality-\nWhenevernecessary,weadjustedunitcostsforinflationbyusing adjusted survival at higher costs. Compared to the standard or\ntheUSConsumerPriceIndextoreflect2017USdollars.24Detailed location-basedstrategies,simplifiedstrategy producedan incre- on Wiley\ninformationisprovidedintheSupportingInformation. mental cost-effectiveness ratio of $10,109 and $10,218 per\nOnline\nQALY,respectively(Table2,Fig.2).\nSensitivityanalysis UseoftheBGCwasassociatedwithreducedutilizationofinva- Library\nOne-way sensitivity analyses were performed by varying the siveprocedures.Withstandardstrategy,atotalof69.3%(95%con-\nfor\nmodelparametersby(cid:1)20%fromthebasecaseoneatthetime. fidence interval [CI], 57.0\u201381.8%) patients underwent these rules\nBecause BGC price was a key determinant of the incremental procedures.Adoptingthelocation-basedstrategyreducedtheuse of\nuse;\ncost-effectiveness ratios, we varied it between $500 and $4,000. of both surgical procedures and TTNA/B, leading the overall\nOA\narticles\nFigure1.Modelstructureforthethreediagnosticstrategiestodetectlungcancerinpatientswithsuspectednodules.Thediagramsshow\n(a)standard,(b)location-basedand(c)simplifieddiagnosticstrategiesinthemodel.Themodelassignsbaselinecharacteristics(age,sex, are\ngoverned\nsmokingstatus,tobaccouse,lesionlocation,POM)toahypotheticalcohortofpeoplewithanincreasedriskofcancer.Patientsareassigned\nadiagnosticpathwayandcancerstatusbasedontheirPOM.Ineachcycle,patientsfollowdifferenthealthtrajectoriesdependingonwhether\ntheyunderwentsurgery,surgical-relateddeath,cancer-relateddeathorbackgroundmortality;probabilitiesofeachareafunctionofPOMand by\nthe\ncancerstatusinthatcycle.Ifapatientsurvivesinagivenyear,thequality-adjustedlife-yearandtotalcostaccruedinthatyearwillbe\napplicable\nrecordedandpatientcharacteristicswillbeupdatedforthenextcycle.Allpatientsarefollowedover2years.Abbreviation:POM,probability\nofmalignancy;BC,bronchoscopy;TTNA-B,transthoracicneedleaspirationorbiopsy;BGC,bronchialgene-expressionclassifier;NB,within\nthenon-diagnosticcategoryareincluded.[Colorfigurecanbeviewedatwileyonlinelibrary.com] Creative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\nD\u2019Andreaetal. 787 2020,\n3,\nDownloaded\nTable2.Resultsofbase-caseanalysesinapopulationatintermediateprobabilityofmalignancy\nfrom\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nSurgicalprocedures1 39.6(32.1\u201348.1) 38.2(30.8\u201346.3) 34.0(26.3\u201342.5)\nTotal 69.3(57.0\u201381.8) 66.0(54.1\u201378.6) 58.9(46.2\u201373.2)\nOveralldeathswithinthe2-yearfollow-up3,%\nSurgery-relateddeath 0.60(0.04\u20131.82) 0.57(0.05\u20131.72) 0.51(0.04\u20131.56)\nWiley\nCost-effectivenessresults\nOynlgineo\nCost,$ 11,111(9,143\u201313,333) 11,093 11,818(9,890\u201314,450) Lliborairym\n(9,116\u201313,320)\non\ne[1d0/0i8p/20E23].r\nIncrementalcost,$ Reference \u221216(\u2212415to334) 708(114\u20131,645)\nSeeec\nthne\nICERrelativetolocation-baseddiagnostic Almostequivalent Reference 10,218 TaeCrms\nstrategy,changein$/changeinQALYs\nand\n1Includingwedgeresection,lobectomyandsegmentectomy. Conditions\n2Attheendoffirstroundscreening(beforethetwoCTscansprogrammedinthewatchfulwaitingapproach).\n3Thebackgroundmortalityisnotincluded.\nAbbreviations:QALYs,quality-adjustedlifeyears;TTNA/B,transthoracicneedleaspirationorbiopsy. (https://onlinelibrary.wiley.com/terms-and-conditions)\nproportionto66%(95%CI,54.1\u201378.6%).Withthesimplifiedstrat- following the current guidelines, 5.56% (95%CI, 3.72\u20138.00%)\negy,thetotalestimatedroppedto58.9(95%CI,46.2\u201373.2%). with the location-based strategy and 7.18% (95%CI,\nThe proportion of cancers that went undetected at the end 4.13\u201311.4%) with the simplified strategy. In the actual clinical\nof the first screening round was 4.65% (95%CI, 3.23\u20136.62%) setting,thesepatientsarereferredtofollow-upandwillundergo\nthe second LDCT. However, in our model, we assumed that\ntheyprogressed toStage IIto penalize BGC-based strategiesfor\n888000000\nLLoocccaattiioonn--bbaasseeddvvss.. falsenegativeresults.\nSSttaaann Cancer-related deaths were 2.65% (95%CI, 1.56\u20133.82%)\nSSiimmmpp under the standard strategy, 2.70% (95%CI, 1.66\u20133.93%) under\nSSttaaann on\nthe location-based strategy and 2.75% (95%CI, 1.61\u20133.83%) Wiley\nunder the simplified strategy. Surgery-related deaths were ))$$\nOnline\n0.60% (95%CI, 0.04\u20131.82%) under the standard strategy,\n0.57% (95%CI, 0.05\u20131.72%) under the location-based strat- Library\negy and 0.51% (95%CI, 0.04\u20131.56%) under the simplified\nfor\nstrategy.Thus,overalldeathswithinthe2-yearfollow-up,exclud- rules\ning background mortality, were 3.25% (95%CI, 1.90\u20134.94%) of\nfollowing the current guidelines, 3.27% (95%CI, 1.98\u20134.88%) II use;\nOA\nadopting the location-based strategy and 3.26% (95%CI, articles\n31.91\u20134.63%)withthesimplifiedstrategy.\nare\ngoverned\n\u2013\u201300..110000 \u2013\u201300..005500 00..000000 00..005500 00..110000\nSensitivityanalysis\nIInn llEEffff )) by\nIn one-way sensitivity analyses, none of the input parameters the\nvaried individually had a large effect on the ICERs other than applicable\nFigure2.Base-caseresultsofincrementalcost-effectivenessoflocation-\nbasedandsimplifieddiagnosticstrategiesversusstandarddiagnostic the sensitivity and price of BGC. Lower sensitivity reduced\nstrategy.[Colorfigurecanbeviewedatwileyonlinelibrary.com] costs and QALYs in both BGC-related strategies compared to Creative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\n788 Cost-effectivenessofabronchialgenomicdevice 2020,\n3,\nDownloaded\nfrom\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nWiley\nOnline\nLibrary\non\n[10/08/2023].\nFigure3.Thegraphshowstheincrementalcosts(verticalaxis;$)fordifferentBGCprices(horizontalaxis)whenlocation-basedstrategyis\ncomparedtostandardstrategy(orangeline)andwhensimplifiedstrategyiscomparedtostandardstrategy(blueline).[Colorfigurecanbe\nviewedatwileyonlinelibrary.com] See\nthe\nTerms\nthe standard (Supporting Information). When the BGC price price at $500 made the location-based strategy cost-saving, by\nis $4,000, thesimplified strategy increases thequality-adjusted uptoabout$300perpatient(Fig.3). and\nlife expectancy at about $1,100 per patient and the location- Figure4showsthecost-effectivenessacceptabilitycurvesof Conditions\nbased strategy at about $100 compared to the standard strat- the probabilistic sensitivity analysis. When the willingness to\negy. If the BGC price is reduced to $500, then the simplified pay per QALY was zero, the location-based strategy was the (https://onlinelibrary.wiley.com/terms-and-conditions)\nstrategy could increase the quality-adjusted life expectancy at optimal diagnostic strategy, followed closely by the standard\nthe same cost as the standard strategy. Reducing the BGC strategy. The simplified strategy had a greater probability to\non\nWiley\nOnline\nLibrary\nfor\nrules\nof\nuse;\nOA\narticles\nare\ngoverned\nby\nthe\nFigure4.Cost-effectivenessacceptabilitycurves(CEAC).Thecurvesindicatetheprobabilityofeachstrategytobecost-effectiveatagiven applicable\nwillingnesstopay(WTP)threshold.ThedotlinesindicatethecommonthresholdsusedfortheUShealthcaresystem.[Colorfigurecanbe\nviewedatwileyonlinelibrary.com]\nCreative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\nD\u2019Andreaetal. 789 2020,\n3,\nDownloaded\nbe cost-effective compared to the others at willingness to pay ensurethataneventualgrowthofmalignanciesisnotrepeatedly\nthresholdsof$20,000orhigherperQALY. perceived or misinterpreted as benign.32 Although our study\nfrom\nshows a slight increase in cancer-related mortality for the\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nDiscussion location-based and simplified strategies, the concomitant\nFor individuals with an indeterminate solid pulmonary nod- decrease in surgery-related deaths keeps the overall mortality\nule, which has risk of developing lung cancer between 5 and roughlyunchanged.Furthermore,itisimportanttonotethatwe\n60%, our analysis suggest that adding a bronchial genomic adopted a very conservative assumption by penalizing BGC-\nclassifier to bronchoscopy for central and peripheral lesions based strategies, for which all undetected cases progressed to\nimprovesquality-adjustedlifeexpectancy,reducesunnecessary Stage II within 1year ignoring the high chance of detection in\ninvasiveproceduresandrepresentsgoodvalueformoneyrela- the follow-up screenings. Thus, it is likely that the difference\ntive to widely-accepted willingness-to-pay thresholds.30 When betweenratesofundetectedcancersandcancer-relatedmortality\nused only for central lesions, the use of the classifier can be isevensmallerthanweobserved.\ncost-savingifitismarketedatlowerprices. Even though the location-based strategy also lowers the\nCompared to the standard, a simplified strategy increases rate of unnecessary procedures, this was not sufficient to pro- Wiley\nthequality-adjusted life expectancy at an acceptable cost. This duce additional clinical benefits and the costs were compara- Oynlgineo\nincrease was mainly due to the net reduction of invasive pro- ble to those for the standard strategy. However, if the price of\ncedures with high risk of complications in patients ultimately the classifier declines, the location-based strategy becomes Lliborairym\ndiagnosed with benign lesions. Even though this genomic test cost-saving, with the potential to reduce health expenditures on\ndoes not eliminate all of the unnecessary procedures (because substantially (e.g., if the price of the classifier were set at e[1d0/0i8p/20E23].r\nof false-negative BGC results), the reduction is sizeable and $1,500wecouldsavealmost$200perperson).\nmight have significant clinical implications, especially since Ourresultsareinlinewiththoseofseveralgenomicclassi-\nSeeec\nfiersfordiagnosisandtherapyofotherconditions.33\u201336Apre-\nthe lung cancer screening has become so widely used in thne\ntheUS. vious cost-effective analysis on a BGC was performed but it TaeCrms\nEight million Americans became eligible for annual LDTC was restricted to the location-based use of bronchoscopy plus and\nlung cancer screening and it is extremely likely that this will classifier vs. bronchoscopy and did not estimate important Conditions\nincreasethenumberofpatientsatintermediateriskunderinves- clinical outcomes that might be a concern for implementation\ntigation.AmongthenodulesthatLDCTdetects,morethan90% such as undetected cancer cases and cancer-related deaths.11\n(https://onlinelibrary.wiley.com/terms-and-conditions)\nare ultimately found to be benign.5 As shown in the NELSON We developed a more comprehensive model, reproducing\ntrial, the volumetric computed tomography might replace the entirely the current process for diagnosis and management of\nLDCT to reduce the risk of unnecessary invasive interventions pulmonary nodules (standard strategy), and then analyzing\nby lowering the rate of false positives to 60%, using a three the use of bronchoscopy plus BGC to replace not only the\nrounds screening strategy.31 However, in the real world, it is bronchoscopy (location-based strategy) but also TTNA/B as\nchallenging to keep a high compliance with the screening for diagnosticexamination(simplifiedstrategy).\nthree consecutive rounds and even with a high adherence, the Our analysis has some limitations. First, we made several\nfalsepositivesarestillamainproblem.False-positiveresultscan assumptionsbasedonthecurrentrecommendations,andwedid\nbe partially resolved by 18F-FDG PET, assuming that all notaccountfortheextenttowhichphysiciansandpatientsactu-\nintermediate-risk patients with an undetermined diagnosis are ally follow them. The clinical management of patients with pul-\nreferredtothisexamination,asrecommendedbytheguidelines.6 monarynodulesmightdifferacrossdiversesettingsandinmany on\nWiley\nHowever, a substantial number of these patients might still situations, the operator experience, the availability of the equip-\nrequireinvasiveprocedures.Adoptingalocation-basedstrategy, ment, patients\u2019 clinical history and preferences or other factors Online\nin which the classifier is used for all nonperipheral lesions, guide the decision. For example, in some circumstances, where Library\nreducesthe rateofinvasive proceduresby3.3% while a simpli- TTNA might be associated with a greater risk of complications,\nfied strategy in which the classifier is used regardless of where bronchoscopythewithendobronchialultrasound(EBUS)isapre- for rules\nlesions are located could reduce the absolute rate of invasive ferred approach to investigate undefined peripheral nodules.37,38\nof\napproachesbymorethan10%. However,becausemostassumptionsaffectallthreestrategiesina use;\nAlthoughthereisanevidentbenefitindecreasingthenumber similarfashion,theconclusionsarelikelytoapplybeyondthepar- OA\narticles\nof unnecessary and/or complicated procedures, in some cases ticularmodelweanalyzed.Second,becausecostsarederivedfrom\nrelyingonafalse-negativeclassifierresultmightdelaythecorrect Medicare databases, accounting for commercial payers\u2019 costs are\ngoverned\ndiagnosis and subsequent treatment. As expected, the rate of wouldarguablyleadtogreateraverageunitcoststhaninouranal-\nundetectedcancersafterthefirstscreeningroundincreasedwith ysis.However,thiswouldincreasethecostsforallstrategiesand\nthe location-based and simplified strategies (by 0.9 and 2.5%, shouldnotaffecttheincrementalresults.Third,werestrictedour by the\nrespectively). However, we assumed that patients with negative analysistodirectmedicalcostsanddidnotconsidertheeffectof applicable\nresults would be referred to surveillance, receiving two further surgical interventions and cancer progression on indirect costs,\nannual LDCT scans. The high sensitivity of LDCT scans can nonmedicalcostsorcostsaccruedfromprolongedlifeexpectancy. Creative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense10970215,\n790 Cost-effectivenessofabronchialgenomicdevice 2020,\n3,\nDownloaded\nFinally,becausethetimehorizonofourmodelis2years,wedid location-based use for central lesions can be cost-saving if the\nnotaccountforallthefuturemedicalcostsrelativetocancerpro- priceofclassifierdeclines.\nfrom\ngressionandtreatment.However,thereisnoreasontobelievethat\nhttps://onlinelibrary.wiley.com/doi/10.1002/ijc.32333,\nthecostoftreatmentwouldbedifferentialacrossthethreestrate-\ngiesbeyondyear2.Thislimitationdoesnotapplytoestimationof Authors\u2019contribution\nquality-adjusted life expectancy, because we have accounted for Study concept: D\u2019Andrea E and Najafzadeh M. Study design:\ntheage-specificlifeexpectancyofpatientsandtheimpactofmor- D\u2019Andrea E, Najafzadeh M and Choudhry NK; Model devel-\ntalityonthatinourmodel. opment and results analysis: D\u2019Andrea E and Najafzadeh\nIn summary, from a health care perspective, adding the M. Interpretation ofthe results:all authors. Initial draft of the\nclassifier to bronchoscopy for the diagnosis of central or article: D\u2019Andrea E; revision of the article: Najafzadeh M,\nperipheral solid nodules could improve health outcomes in Choudhry NK, Raby B and Weinhouse GL. Final version\npatients with indeterminate nodules at acceptable cost. The approval:allauthors.\nReferences Wiley\nOnline\n1. SiegelRL,MillerKD,JemalA.Cancerstatistics, 14. GouldMK,MacleanCC,KuschnerWG,etal. 26. BriggsAH.Handlinguncertaintyincost-effectiveness\n2017.CACancerJClin2017;67:7\u201330. Accuracyofpositronemissiontomographyfor models.Pharmacoeconomics2000;17:479\u2013500. Library\n2. NationalLungScreeningTrialResearchTeam, diagnosisofpulmonarynodulesandmasslesions: 27. SpiegelhalterDJ,BestNG.Bayesianapproachesto\nAberleDR,AdamsAM,etal.Reducedlung-cancer ameta-analysis.JAMA2001;285:914\u201324. multiplesourcesofevidenceanduncertaintyin on\nmortalitywithlow-dosecomputedtomographic 15. GouldMK,SandersGD,BarnettPG,etal.Cost- complexcost-effectivenessmodelling.StatMed [10/08/2023].\nscreening.NEnglJMed2011;365:395\u2013409. effectivenessofalternativemanagementstrategies 2003;22:3687\u2013709.\n3. MarcusPM,Doria-RoseVP,GareenIF,etal.Did forpatientswithsolitarypulmonarynodules.Ann 28. MoyerVA,PreventiveServicesTaskForceUS.\ndeathcertificatesandadeathreviewprocessagree InternMed2003;138:724\u201335. Screeningforlungcancer:U.S.PreventiveServices\nonlungcancercauseofdeathintheNational 16. YangCF,SunZ,SpeicherPJ,etal.Useandout- TaskForcerecommendationstatement.Ann See\nLungScreeningTrial?ClinTrials2016;13:434\u20138. comesofminimallyinvasivelobectomyforstageI InternMed2014;160:330\u20138. the\n4. MassionPP,WalkerRC.Indeterminatepulmo- non-smallcelllungcancerintheNationalCancer 29. CentersforMedicareandMedicaidServices Terms\nnarynodules:riskforhavingorfordeveloping DataBase.AnnThoracSurg2016;101:1037\u201342. (CMS).DecisionMemoforScreeningforLung\nand\nlungcancer?CancerPrevRes(Phila)2014;7: 17. InternationalEarlyLungCancerActionProgram CancerwithLowDoseComputedTomography\n1173\u20138. Investigators,HenschkeCI,YankelevitzDF,etal. (LDCT)(CAG-00439N).Availableat:https://www. Conditions\n5. BachPB,MirkinJN,OliverTK,etal.Benefitsand SurvivalofpatientswithstageIlungcancer cms.gov/medicare-Coverage-database/details/nca-\nharmsofCTscreeningforlungcancer:asystem- detectedonCTscreening.NEnglJMed2006;355: decision-memo.aspx?NCAId=274[datelast\n(https://onlinelibrary.wiley.com/terms-and-conditions)\naticreview.JAMA2012;307:2418\u201329. 1763\u201371. accessedDecember20,2018].\n6. GouldMK,DoningtonJ,LynchWR,etal.Evalu- 18. WisniveskyJP,HenschkeC,McGinnT,etal. 30. NeumannPJ,CohenJT,WeinsteinMC.Updating\nationofindividualswithpulmonarynodules: PrognosisofstageIInon-smallcelllungcancer cost-effectiveness\u2014thecuriousresilienceofthe\nwhenisitlungcancer?Diagnosisandmanage- accordingtotumorandnodalstatusatdiagnosis. $50,000-per-QALYthreshold.NEnglJMed2014;\nmentoflungcancer,3rded:AmericanCollegeof LungCancer2005;49:181\u20136. 371:796\u20137.\nChestPhysiciansevidence-basedclinicalpractice 19. TrippoliS,VaianiM,LucioniC,etal.Qualityof 31. HorewegN,vanderAalstCM,VliegenthartR,\nguidelines.Chest2013;143:E93S\u2013E120S. lifeandutilityinpatientswithnon-smallcelllung etal.Volumetriccomputedtomographyscreening\n7. RiveraMP,MehtaAC,WahidiMM.Establishing cancer.Quality-of-lifeStudyGroupoftheMaster forlungcancer:threeroundsoftheNELSON\nthediagnosisoflungcancer:diagnosisandman- 2projectinPharmacoeconomics. trial.EurRespirJ2013;42:1659\u201367.\nagementoflungcancer,3rded:AmericanCollege Pharmacoeconomics2001;19:855\u201363. 32. vanKlaverenRJ,OudkerkM,ProkopM,etal.\nofChestPhysiciansevidence-basedclinicalprac- 20. NafeesB,StaffordM,GavrielS,etal.Healthstate Managementoflungnodulesdetectedbyvolume\nticeguidelines.Chest2013;143:E142S\u201365S. utilitiesfornon-smallcelllungcancer.Health CTscanning.NEnglJMed2009;361:2221\u20139.\n8. CheungLC,KatkiHA,ChaturvediAK,etal. QualLifeOutcomes2008;6:84. 33. LiH,RobinsonKA,AntonB,etal.Cost-\nPreventinglungcancermortalitybycomputed 21. SullivanPW,GhushchyanV.Preference-based effectivenessofanovelmoleculartestforcytologi-\non\ntomographyscreening:theeffectofrisk-basedversus EQ-5Dindexscoresforchronicconditionsinthe callyindeterminatethyroidnodules.JClin Wiley\nU.S.PreventiveServicesTaskForceeligibilitycriteria, UnitedStates.MedDecisMaking2006;26:410\u201320. EndocrinolMetab2011;96:E1719\u201326.\n2005-2015.AnnInternMed2018;168:229\u201332. 22. CentersforMedicare&MedicaidServices(CMS). 34. YipL,FarrisC,KabakerAS,etal.Costimpactof Online\n9. SilvestriGA,VachaniA,WhitneyD,etal.A MedicarePhysicianFeeSchedule(MPFS).Avail- moleculartestingforindeterminatethyroidnod-\nbronchialgenomicclassifierforthediagnostic ableat:www.cms.gov/apps/physician-fee- ulefine-needleaspirationbiopsies.JClin Library\nevaluationoflungcancer.NEnglJMed2015;373: schedule/overview.aspx[datelastaccessed EndocrinolMetab2012;97:1905\u201312.\n243\u201351. December7,2018]. 35. LoboJM,TrifilettiDM,SturzVN,etal.Cost- for\n10. VachaniA,WhitneyDH,ParsonsEC,etal.Clini- 23. CentersforMedicare&MedicaidServices(CMS). effectivenessofthedeciphergenomicclassifierto rules\ncalutilityofabronchialgenomicclassifierin HospitalOutpatientProspectivePayment(HOPP) guideindividualizeddecisionsforearlyradiation of\npatientswithsuspectedlungcancer.Chest2016; FeeSchedule.Availableat:www.cms.gov/ therapyafterprostatectomyforprostatecancer. use;\n150:210\u20138. Medicare/Medicare-Fee-for-Service-Payment/ ClinGenitourinCancer2017;15:E299\u2013309. OA\n11. Feller-KopmanD,LiuS,GeislerBP,etal.Cost- HospitalOutpatientPPS/Hospital-Outpatient- 36. D\u2019AndreaE,MarzuilloC,PeloneF,etal.Genetic articles\neffectivenessofabronchialgenomicclassifierfor Regulations-and-Notices-Items/CMS-1613-CN. testingandeconomicevaluations:asystematicreview\nthediagnosticevaluationoflungcancer.JThorac html?DLPage=1&DLSort=2&DLSortDir= oftheliterature.EpidemiolPrev2015;39:45\u201350. are\nOncol2017;12:1223\u201332. descending[datelastaccessedDecember72018]. 37. Mu\u00f1oz-LargachaJA,LitleVR,FernandoHC. governed\n12. ZhaoZR,SituDR,LauRWH,etal.Comparison 24. BureauofLaborStatistics.CPIinflationcalculator. Navigationbronchoscopyfordiagnosisandsmall\nofSegmentectomyandlobectomyinstageIAade- 2017.Availableat:www.bls.gov/data/inflation_ nodulelocation.JThoracDis2017;9:S98\u2013S103.\nnocarcinomas.JThoracOncol2017;12:890\u20136. calculator.htm[datelastaccessedDecember4,2018]. 38. FolchEE,PritchettMA,NeadMA,etal.Electro- by\nthe\n13. FergusonJS,VanWertR,ChoiY,etal.Impactof 25. ClaxtonK,SculpherM,McCabeC,etal.Probabi- magneticnavigationbronchoscopyforperipheral applicable\nabronchialgenomicclassifieronclinicaldecision listicsensitivityanalysisforNICEtechnology pulmonarylesions:one-yearresultsofthepro-\nmakinginpatientsundergoingdiagnosticevalua- assessment:notanoptionalextra.HealthEcon spective,multicenterNAVIGATEstudy.JThorac\ntionforlungcancer.BMCPulmMed2016;16:66. 2005;14:339\u201347. Oncol2019;14:445\u201358. Creative\nCommons\nInt.J.Cancer:146,781\u2013790(2020)\u00a92019UICC\nLicense"
}